nominally significantp = 0.026
Interestingly, in a meta‐analysis including 11 359 patients receiving therapy within 16 h of admission for acute heart failure in the serelaxin development program, serelaxin was associated with a nominally significant 13% reduction in all‐cause mortality (95% CI 0.77–0.98; p = 0.026). 10 In this current substudy, serelaxin treatment was associated with a 45% reduction in in‐hospital worsening heart failure.